Primary, or essential, hypertension is defined as persistently elevated blood pressure without any identifiable cause. It is a major risk factor for various cardiovascular diseases (e.g., coronary artery disease, stroke, heart failure), renal failure, and death. Hypertension is treated with a large array of drugs, and guidelines emphasize the additive effects of using two or more drugs from different antihypertensive drug classes. Despite numerous treatment options, significant unmet need remains for patients with resistant hypertension, in whom concurrent use of three or more antihypertensive agents does not adequately control blood pressure.

QUESTIONS ANSWERED

  • Which drug attributes most strongly influence antihypertensive drug selection?
  • How do cardiologists rate key current antihypertensive therapies across select drug attributes?
  • Where are the hidden opportunities for drug development in the hypertension therapy market?
  • Do U.S. and European cardiologists have different perceptions of the unmet need in the treatment of hypertension?

PRODUCT DESCRIPTION

Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 30 European cardiologists

Key drugs: ACE inhibitors, ARBs, diuretics, calcium-channel blockers, beta blockers, aldosterone antagonists

Table of contents

  • Hypertension - Unmet Need - Detailed, Expanded Analysis 2020

Author(s): Dwaipayan Chatterjee, M.Pharm

Dwaipayan Chatterjee is an Analyst in the Cardiovascular, Metabolism Renal and Hematology disease team at Decision Resources Group.

He holds a M.Pharm degree with specialization in Pharmaceutical Chemistry from Birla Institute of Technology & Science, Pilani, Rajasthan, India. Prior joining DRG, he worked as an Equity Analyst for the U.S. Healthcare sector with Market Realist working on competitive intelligence and analysis of pharmaceutical financial data. He also worked as a market research analyst for Mordor Intelligence with experience of market sizing, forecasting, and analyzing market dynamics.


Related Reports

Pulmonary Hypertension - Current Treatment - Detailed, Expanded Analysis (EU5)

Pulmonary hypertension (PH) is a rare and life-threatening disorder marked by considerable morbidity and mortality. Off-label drug use is widespread because drugs have been approved only for the tr...

View Details

Pulmonary Hypertension - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis - Pulmonary Arterial Hypertension (US)

Instructions for uploading your PowerPoint presentation and survey:Pulmonary arterial hypertension (PAH

View Details

Pulmonary Hypertension - Landscape & Forecast - Disease Landscape & Forecast

Pulmonary hypertension (PH) is a devastating disease with high levels of morbidity and mortality and no cure. Despite the disease’s rarity, the pot...

View Details

Pulmonary Hypertension - Epidemiology - Extrapolated Worldwide Coverage

DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key pulmonary hypertension patie...

View Details